Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Lymphoid 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Hodgkin Disease 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × TKM-080301 × Clear all
NCT01262235 2019-01-16

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

Phase 1/2 Completed
68 enrolled
EndocrineLymphoidNET

Carcinoid Tumor, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT02191878 2019-01-16

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

Arbutus Biopharma Corporation

Phase 1/2 Completed
43 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡